Skip to main content
SpringerLink
Log in

Teprotumumab for Graves’ orbitopathy and ototoxicity: moving problems from eyes to ears?

  • Opinion
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bartalena L, Tanda ML (2009) Clinical practice. Graves’ ophthalmopathy. N Engl J Med 360:994–1001. https://doi.org/10.1056/NEJMcp0806317

    Article  CAS  PubMed  Google Scholar 

  2. Bartalena L, Kahaly GJ, Baldeschi L et al (2021) The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol 185:G43–G67. https://doi.org/10.1530/EJE-21-0479

    Article  CAS  PubMed  Google Scholar 

  3. Smith TJ, Kahaly GJ, Ezra DG et al (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376:1748–1761. https://doi.org/10.1056/NEJMoa1614949

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Douglas RS, Kahaly GJ, Patel A et al (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382:341–352. https://doi.org/10.1056/NEJMoa1910434

    Article  CAS  PubMed  Google Scholar 

  5. Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ (2021) Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol 9:360–372. https://doi.org/10.1016/S2213-8587(21)00056-5

    Article  CAS  PubMed  Google Scholar 

  6. Hoang TD, Nguyen NT, Chou E, Skakir MKM (2021) Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease. BMJ Case Rep 14:e242153. https://doi.org/10.1136/bcr-2021-242153

    Article  PubMed  PubMed Central  Google Scholar 

  7. Safo MB, Silkiss RZ (2021) A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease. Am J Ophthalmol Case Rep 22:101069. https://doi.org/10.1016/j.ajoc.2021.101069

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ashraf DC, Jankovic I, El-Nachef N, Winn BJ, Kim GE, Kersten RC (2021) New-onset of inflammatory bowel disease in a patient treated with teprotumumab for thyroid associated ophthalmopathy. Ophthalmic Plast Reconstr Surg 37:e160–e164. https://doi.org/10.1097/IOP.0000000000001943

    Article  PubMed  Google Scholar 

  9. Douglas RS, Kahaly GJ, Ugradar S et al (2021) Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology. https://doi.org/10.1016/j.ophtha.2021.10.017

    Article  PubMed  Google Scholar 

  10. Douglas RS, Wang Y, Dailey RA et al (2021) Teprotumumab in clinical practice: recommendations and considerations from the OPTIC trial investigators. J Neuroophthalmol 41:461–468. https://doi.org/10.1097/WNO.0000000000001134

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sears CM, Azad AD, Amarikwa L et al (2022) Hearing dysfunction after treatment with teprotumumab for thyroid eye disease. Am J Ophthalmol. https://doi.org/10.1016/j.ajo.2022.02.015

    Article  PubMed  Google Scholar 

  12. Belinsky I, Creighton FX, Mahoney NR et al (2022) Teprotumumab and hearing loss: case series and proposal for audiologic monitoring. Ophthalmic Plast Reconstr Surg 38:73–78. https://doi.org/10.1097/IOP.0000000000001995

    Article  PubMed  Google Scholar 

  13. Ding AS, Mahoney NR, Campbell AA, Creighton FX (2022) Sensorineural hearing loss after teprotumumab therapy for thyroid eye disease: a case report. Otol Neurotol 43:e148–e152. https://doi.org/10.1097/MAO.0000000000003428

    Article  PubMed  Google Scholar 

  14. Gao L, Kita T, Katsuno T, Yamamoto N, Omori K, Nakagawa T (2020) Insulin-like growth factor 1 on the maintenance of ribbon synapses in mouse cochlear explant cultures. Front Cell Neurosci 14:571155. https://doi.org/10.3389/fncel.2020.571155

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yamamoto N, Nakagawa T, Ito J (2014) Application of insulin-like growth factor-1 in the treatment of inner ear disorders. Front Pharmacol 5:208. https://doi.org/10.3389/fphar.2014.00208

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Martinez-Amezcua P, Powell D, Kuo P-L, Reed NS, Sullivan KJ, Palta P et al (2021) Association of age-related hearing impairment with physical functioning among community-dwelling older adults in the US. JAMA Netw Open 4:e2113742. https://doi.org/10.1001/jamanetworkopen.2021.13742

    Article  PubMed  PubMed Central  Google Scholar 

  17. Genther DJ, Frick KD, Chen D, Betz J, Lin FR (2013) Association of hearing loss with hospitalization and burden of disease in older adults. JAMA 309:2322–2324. https://doi.org/10.1001/jama.2013.5912

    Article  CAS  PubMed  Google Scholar 

  18. Livingston G, Sommerlad A, Orgeta V et al (2017) Dementia prevention, intervention, and care. Lancet 290:2673–2734. https://doi.org/10.1016/s0140-6736(17)31363-6

    Article  Google Scholar 

  19. Ugradar S, Kang J, Kossler AL et al (2021) Teprotumumab for the treatment of chronic eye disease. Eye. https://doi.org/10.1038/s41433-021-01593-z

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Emeritus Professor of Endocrinology, Department of Medicine and Surgery, University of Insubria, Via Guicciardini, 9, 21100, Varese, Italy

    L. Bartalena & M. L. Tanda

  2. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

    M. Marinò & C. Marcocci

Authors
  1. L. Bartalena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Marinò
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Marcocci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. L. Tanda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Bartalena.

Ethics declarations

Conflict of interest

The authors have no conflict of interest to declare. LB is the Editor-in-Chief, and MM and MLT are members of the Editorial Board of the Journal of Endocrinological Investigation.

Ethical approval

No approval from the Institutional Ethics Committee was needed.

Informed consent

The article did not involve humans; therefore, no informed consent was needed.

Research involving human participants and/or animals

No research involving human participants and/or animals was carried out in this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bartalena, L., Marinò, M., Marcocci, C. et al. Teprotumumab for Graves’ orbitopathy and ototoxicity: moving problems from eyes to ears?. J Endocrinol Invest 45, 1455–1457 (2022). https://doi.org/10.1007/s40618-022-01791-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-022-01791-w

Keywords

Search

Navigation